TY - JOUR T1 - First Experiences with <sup>177</sup>Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 975 LP - 978 DO - 10.2967/jnumed.120.249029 VL - 62 IS - 7 AU - Vikas Prasad AU - Friedemann Zengerling AU - Jochen P. Steinacker AU - Christian Bolenz AU - Meinrad Beer AU - Thomas Wiegel AU - Matthias Eiber AU - Neil Fleshner AU - Ambros J. Beer Y1 - 2021/07/01 UR - http://jnm.snmjournals.org/content/62/7/975.abstract N2 - Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be used to overcome the limitations of radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA) in metastasized castration-resistant prostate cancer. Here, we present 2 patients receiving such combination or sequential therapies. Methods: RLT was performed at 6- to 8-wk intervals after the patients either exhausted or were considered unfit for all approved conventional treatments. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 received RLT sequentially 4 wk after 3 mo of monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed a radiologic and biochemical response, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients. ER -